¼¼°èÀÇ ºÎ½Å°æÀýÁ¾ ½ÃÀå º¸°í¼­(2025³â)
Paraganglioma Global Market Report 2025
»óǰÄÚµå : 1720854
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºÎ½Å°æÀýÁ¾ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ ½ÅÈï ½ÃÀåÀÇ ÇコÄÉ¾î ¾×¼¼½º °³¼± µî¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â Ç¥Àû¿ä¹ýÀÇ ÁøÀü, ¹æ»ç¼ºÀǾàǰÀÇ È®´ë, ¸é¿ª¿ä¹ý Á¢±ÙÀÇ ´ëµÎ, Áø´Ü¿¡ À־ÀÇ ÀΰøÁö´É(AI)ÀÇ ÀÌ¿ë °­È­, Àúħ½À ¼ö¼ú±â¼úÀÇ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

Á¾¾çÇÐ ¿¬±¸ ¹× ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚÀÇ È®´ë°¡ ÇâÈÄ ¸î ³â°£ÀÇ Á¾¾çÇÐ ¿¬±¸ ¹× ÀÇ·á ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÅõÀÚ Áõ°¡´Â ¼¼°èÀÇ ¾Ï ÀÌȯÀ² »ó½Â, Á¤¹ÐÀÇ·á Áøº¸, Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÓ»ó °Ë»ç È®´ë, Á¤ºÎ ¹× ¹Î°£ ÀÚ±Ý Á¦°ø ÀÌ´Ï¼ÅÆ¼ºê, Ç¥Àû ¿ä¹ý ¹× ¸é¿ª ¿ä¹ýÀÇ °³¹ß¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¼±ÅÃÀÇ °­È­, º¸´Ù È¿°úÀûÀÎ ¾àÁ¦ÀÇ ÀÓ»ó °Ë»ç¿¡ÀÇ ÀÚ±Ý Á¦°ø, ¼Ò¾Æ¾Ï Ä¡·áÀÇ ÀÎÇÁ¶ó °­È­, ÁúȯÀÇ »ý¹°ÇÐÀû ¼ºÁú°ú ÁøÇàÀÇ ÀÌÇØ¸¦ ±í°Ô Çϱâ À§ÇÑ Çõ½ÅÀû ¿¬±¸ÀÇ ÃËÁø µî¿¡ ÀÇÇØ ºÎ½Å°æÀýÁ¾ÀÇ Áøº¸¸¦ ÁöÁöÇϰí ÀÖ½À´Ï´Ù. IQVIA´Â 2023³â ¼¼°èÀÇ ¾Ï ÀÇ·á¿¡ ´ëÇÑ ÁöÃâÀÌ 2022³âºÎÅÍ 250¾ï ´Þ·¯ Áõ°¡ÇÑ 2,230¾ï ´Þ·¯·Î Áõ°¡Çϰí, 2028³â¿¡´Â 4,090¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

ºÎ½Å°æÀýÁ¾ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °æ±¸ Àú»ê¼Ò À¯µµ ÀÎÀÚ-2¥á(HIF-2a) ¾ïÁ¦Á¦¿Í °°Àº °í±Þ Ä¡·áÀÇ °³¹ßÀ» ¼±È£Çϰí ȯÀÚ¿¡°Ô Ç¥Àû Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¿äÀÎÀÎ HIF-2a Ȱ¼ºÀ» ÀúÇØÇϴ ǥÀû Ä¡·áÀ̸ç, ÀÌ·Î½á ºÎ½Å°æÀýÁ¾°ú °°Àº »óÅ¿¡¼­ÀÇ ¾ÏÀÇ ÁøÇàÀ» Áö¿¬½Ãŵ´Ï´Ù. 2025³â 1¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ ¹ÙÀÌ¿À Á¦¾à ȸ»çÀÎ ¸ÓÅ©´Â ¹Ì±¹ Á¤ºÎ ±â°üÀÎ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ À£¸®·º(º§ÁÖÆ¼ÆÇ)¿¡ ´ëÇÑ Ãß°¡ ½Å¾à ½ÅûÀÌ ¿ì¼± °ËÅ並 ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. À£¸®·ºÀº ÁøÇ༺, ÀýÁ¦ ºÒ°¡´É¼º ¶Ç´Â ÀüÀ̼º °¥»ö¼¼Æ÷Á¾°ú ºÎ±³¼¼Æ÷Á¾(PPGL)À» °¡Áø ¼ºÀÎ ¹× ¼Ò¾Æ ȯÀÚ(12¼¼ ÀÌ»ó)¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Paraganglioma is a rare neuroendocrine tumor that arises from paraganglia, clusters of cells associated with the autonomic nervous system. These tumors are typically found in the head, neck, chest, or abdomen and may produce excess hormones, posing a risk of malignancy. Early diagnosis is crucial for effective management and preventing complications.

The main types of paraganglioma include sympathetic, parasympathetic, carotid, cervical, jugular, secretory, and temporal paragangliomas. Sympathetic paragangliomas, which develop in the sympathetic nervous system, often produce catecholamines. These tumors originate from various locations, such as the head and neck, abdomen, pelvis, and other areas. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, catering to end-users such as hospitals, specialty clinics, and cancer research institutes.

The paraganglioma market research report is one of a series of new reports from The Business Research Company that provides paraganglioma market statistics, including the paraganglioma industry global market size, regional shares, competitors with the paraganglioma market share, detailed paraganglioma market segments, market trends, and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increased awareness and screening programs, regulatory approvals for targeted therapies, the expansion of specialized treatment centers, and progress in genetic testing.

The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies and immunotherapies, the expansion of radiopharmaceuticals, the rising prevalence of genetic diseases, increasing investments in rare disease research, and improved healthcare access in emerging markets. Major trends expected during this period include advancements in targeted therapies, the expansion of radiopharmaceuticals, the rise of immunotherapy approaches, enhanced use of artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.

The growing investments in oncology research and medicine are expected to drive the expansion of the paraganglioma market in the coming years. Investments in oncology research and medicine refer to financial commitments made by governments, pharmaceutical companies, research institutions, and private investors to advance cancer prevention, diagnosis, and treatment. The increase in such investments is fueled by the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support advancements in paraganglioma by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to better understand the disease's biology and progression. For instance, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, the increasing investments in oncology research and medicine are fueling the growth of the paraganglioma market.

Leading companies in the paraganglioma market are prioritizing the development of advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors to provide targeted treatment options for patients. An oral HIF-2a inhibitor is a targeted therapy that inhibits HIF-2a activity, a key factor in tumor growth under low-oxygen conditions, thereby slowing cancer progression in conditions such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that its supplemental new drug application for Welireg (belzutifan) received priority review from the U.S. Food and Drug Administration (FDA), a US-based government agency. Welireg is intended for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The supplemental new drug application (sNDA) is supported by objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.

In January 2022, Exact Sciences Corp., a US-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed amount. This acquisition was aimed at expanding Exact Sciences' hereditary cancer testing capabilities, increasing access to early detection and personalized treatment options. PreventionGenetics, a US-based clinical genetic testing laboratory, specializes in genetic testing for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.

Major players in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John's Cancer Institute.

North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paraganglioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paraganglioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paraganglioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for paraganglioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paraganglioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Paraganglioma Market Characteristics

3. Paraganglioma Market Trends And Strategies

4. Paraganglioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Paraganglioma Growth Analysis And Strategic Analysis Framework

6. Paraganglioma Market Segmentation

7. Paraganglioma Market Regional And Country Analysis

8. Asia-Pacific Paraganglioma Market

9. China Paraganglioma Market

10. India Paraganglioma Market

11. Japan Paraganglioma Market

12. Australia Paraganglioma Market

13. Indonesia Paraganglioma Market

14. South Korea Paraganglioma Market

15. Western Europe Paraganglioma Market

16. UK Paraganglioma Market

17. Germany Paraganglioma Market

18. France Paraganglioma Market

19. Italy Paraganglioma Market

20. Spain Paraganglioma Market

21. Eastern Europe Paraganglioma Market

22. Russia Paraganglioma Market

23. North America Paraganglioma Market

24. USA Paraganglioma Market

25. Canada Paraganglioma Market

26. South America Paraganglioma Market

27. Brazil Paraganglioma Market

28. Middle East Paraganglioma Market

29. Africa Paraganglioma Market

30. Paraganglioma Market Competitive Landscape And Company Profiles

31. Paraganglioma Market Other Major And Innovative Companies

32. Global Paraganglioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paraganglioma Market

34. Recent Developments In The Paraganglioma Market

35. Paraganglioma Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â